Lundbeck launches "Say Yep" campaign for migraine drug in the US
The message from the Danish pharmaceutical company to the approximately 40 million American migraine sufferers is to slow down and not push through the pain during migraine attacks.
Denmark-based Lundbeck wants migraine sufferers to say ”no” to doing more and ”yes” to doing less in a new campaign in the US for its migraine drug Vyepti, which was approved in Europe in January 2022, while in the US it was launched in April 2020.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
